Fred Alger Management, LLC Intra Cellular Therapies, Inc. Transaction History

Fred Alger Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $260,982 - $321,755	4,030 Added 32.15%	16,564 $1.13 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $806,813 - $948,197	12,534 New	12,534 $867,000
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $1.97 Million - $2.77 Million	-46,184 Reduced 54.51%	38,536 $1.79 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $903,344 - $1.38 Million	-21,008 Reduced 19.87%	84,720 $4.84 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $4.1 Million - $6.56 Million	105,728 New	105,728 $6.47 Million
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $285,400 - $335,800	-20,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $215,400 - $442,000	20,000	20,000 $316,000

378

84.1M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.9B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.